You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HER2 Exon 20 Mutation

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation Trial in Fairfax (STX-721)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • +2 more
  • Fairfax, Virginia
    NEXT Virginia
Sep 18, 2023

EGFR Exon 20 Mutation, ERBB2 Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma Trial in Houston (Poziotinib)

Recruiting
  • EGFR Exon 20 Mutation
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 12, 2022

NSCLC Trial in Worldwide (Afatinib)

Completed
Has Results
  • NSCLC
  • Köln, Germany
  • +4 more
Aug 23, 2022

NSCLC, Stage IV, NSCLC Stage IIIB, NSCLC, Stage IIIC Trial in Canada, Hong Kong, United States (tarloxotinib bromide)

Terminated
  • NSCLC, Stage IV
  • +7 more
  • tarloxotinib bromide
  • Irvine, California
  • +13 more
Nov 11, 2021

NSCLC Trial in Winter Haven (Poziotinib, Docetaxel)

Suspended
  • NSCLC
  • Winter Haven, Florida
    Bond Clinic, P.A.
Jan 27, 2023

NSCLC Trial in Worldwide (Poziotinib)

Active, not recruiting
  • NSCLC
  • Phoenix, Arizona
  • +62 more
Jan 27, 2023

Non-squamous NSCLC, HER2 Exon 20 Mutation Trial in Worldwide (Pyrotinib, Docetaxel)

Recruiting
  • Non-squamous NSCLC
  • HER2 Exon 20 Mutation
  • Orange, California
  • +102 more
Oct 18, 2021

NSCLC Trial in China, Korea, Republic of (Poziotinib)

Terminated
  • NSCLC
  • Beijing, China
  • +25 more
Nov 16, 2020

NSCLC Trial in Shanghai (Furmonertinib 160mg, Furmonertinib 240mg)

Recruiting
  • NSCLC
  • Furmonertinib 160mg
  • Furmonertinib 240mg
  • Shanghai, China
    Shanghai Chest hospital
Jan 16, 2023

Non-squamous NSCLC Trial (biological, drug, dietary supplement)

Not yet recruiting
  • Non-squamous NSCLC
  • Pembrolizumab
  • +7 more
  • (no location specified)
Feb 20, 2023

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations Trial in

Recruiting
  • Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
  • Canton, Ohio
    Gabrail Cancer and Research Center
Jul 21, 2023

NSCLC Trial in Guangzhou (PLB1001)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Guangdong Provincial People's Hospital
Aug 15, 2023

Gastrointestinal Stromal Tumors Trial in Houston (Regorafenib)

Not yet recruiting
  • Gastrointestinal Stromal Tumors
  • Houston, Texas
    M D Anderson Cancer Center
Oct 12, 2023

Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation Trial in Canton (TAS6417)

Recruiting
  • Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
  • Canton, Ohio
    Gabrail Cancer and Research Center
Jul 25, 2023

Learn About Tests Looking forGene Mutation in Lung Cancer in

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • No Intervention
  • Beijing, China
    Department of Pathology, National Cancer Center/National Clinica
Feb 24, 2023

NSCLC, RET Driver Mutation, BRAF V600 Mutation Trial in Guanzhou (Toripalimab, Nab paclitaxel, Pemetrexed)

Recruiting
  • Non-Small Cell Lung Cancer
  • +5 more
  • Toripalimab
  • +3 more
  • Guanzhou, Guangdong, China
    Guangdong Lung Cancer Institute, Guangdong Provincial People's H
Apr 4, 2023

Lung Tumor Malignant, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-451)

Recruiting
  • Lung Neoplasm Malignant
  • +18 more
  • Fairfax, Virginia
    New Experimental Therapeutics of Virginia (NEXT Oncology)
Mar 29, 2022

Locally Advanced or Metastatic NSCLC Trial in Seoul (Osimertinib 80 MG [Tagrisso])

Completed
  • Locally Advanced or Metastatic NSCLC
  • Osimertinib 80 MG [Tagrisso]
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Sep 22, 2021

Advanced Malignant Solid Tumor, EGFR Gene Amplification, EGFR Gene Mutation Trial in Houston (Everolimus, Neratinib,

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 25, 2022

NSCLC Trial in Shanghai (RC48-ADC, Pyrotinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Feb 16, 2023

HER2, Colorectal Cancer Trial (Disitamab Vedotin Combined With Fruquintinib)

Not yet recruiting
  • HER2
  • Colorectal Cancer
  • Disitamab Vedotin Combined With Fruquintinib
  • (no location specified)
Dec 21, 2022

Breast Cancer, Ovarian Cancer, Breast Tumors Trial in Dnipro, Kyiv (Axitinib)

Enrolling by invitation
  • Breast Cancer
  • +7 more
  • Dnipro, Ukraine
  • +1 more
Jun 17, 2023

NSCLC Trial in Shanghai (Furmonertinib 240mg, Furmonertinib 160mg)

Withdrawn
  • NSCLC
  • Furmonertinib 240mg
  • Furmonertinib 160mg
  • Shanghai, China
    Shanghai Chest hospital
Oct 17, 2021

NSCLC Trial (Furmonertinib)

Not yet recruiting
  • NSCLC
  • (no location specified)
Jul 17, 2022

Her-2 Negative Breast Cancer, HRR Gene Mutation Trial in Guangzhou (Camrelizumab, Fluzoparib, Nab-paclitaxel)

Recruiting
  • Her-2 Negative Breast Cancer
  • HRR Gene Mutation
  • Guangzhou, Guangdong, China
    First Affiliated Hospital, Sun Yat-Sen University
Mar 7, 2023